ACULAR

LOE Approaching

ketorolac tromethamine

NDAOPHTHALMICSOLUTION/DROPS
Approved
Nov 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis.

Clinical Trials (5)

NCT07425522Phase 1Not Yet Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)

Started Apr 2026
93 enrolled
Diabetic Macular Edema
NCT07441642Phase 2Recruiting

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Started Mar 2026
272 enrolled
Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07007065Phase 3Recruiting

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Started Nov 2025
561 enrolled
Neovascular Age-related Macular Degeneration
NCT07215234Phase 1/2Recruiting

A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Started Oct 2025
104 enrolled
Geographic Atrophy
NCT07228559Phase 1Recruiting

A Study of Avoralstat In Participants With Diabetic Macular Edema

Started Oct 2025
9 enrolled
Diabetic Macular Edema (DME)